Products for Research Use Only
RegisterLogin

(E/Z) -Afatinib

CAT: 0804-HY-10261B-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10261B-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(E/Z) -Afatinib ((E/Z) -BIBW 2992) is the mixture of (E) -Afatinib and (Z) -Afatinib. Afatinib is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells[1].
CAS Number
439081-18-2
Product Name Alternative
(E/Z) -BIBW 2992
UNSPSC
12352005
Hazard Statement
H302, H319, H373
Target
Akt; Apoptosis; Autophagy; c-Met/HGFR; EGFR; p38 MAPK
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Others; Cancer
Assay Protocol
https://www.medchemexpress.com/e-z-afatinib.html
Purity
99.98
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(/C=C/CN(C)C)NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4
Molecular Formula
C24H25ClFN5O3
Molecular Weight
485.94
Precautions
H302, H319, H373
References & Citations
[1]Yoshioka T, et al. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. Cancer Sci. 2018 Apr;109 (4) :1166-1176.|[2]Wang XK, et al. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget. 2014 Dec 15;5 (23) :11971-85.|[3]Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7;27 (34) :4702-11.|[4]Wong CH, et al. Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC) . Am J Cancer Res. 2015 Nov 15;5 (12) :3588-99.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10261-01Afatinib
HY-B0823A(E/Z) -Acetamiprid
HY-N1214A(E/Z) -Squalene
HY-137451A-01(E/Z) -Sivopixant
HY-145915A-01(E/Z) -ZINC09659342
HY-13779-01(E/Z) -J147
HY-W230975(E/Z) -Piperine
HY-15338A-01(E/Z) -TG003
HY-101284A-01(E/Z) -DMU2105
HY-112149A-01(E/Z) -ZL0420

Alternative Products

CatalogName
A10141-1000(E/Z) -BIBW2992 (E/Z-Afatinib) 1g
A10141-500(E/Z) -BIBW2992 (E/Z-Afatinib) 500mg
A10141-200(E/Z) -BIBW2992 (E/Z-Afatinib) 200mg
AR-A01485-01Afatinib Impurity D (Z-Afatinib)
RM-A062026-01Afatinib Impurity Z
RM-A062005-01Afatinib Impurity E
PC1001065(E) -N- (4- ((3-Chloro-4-fluorophenyl) amino) -7-fluoroquinazolin-6-yl) -4- (dimethylamino) but-2-enamide (Afatinib Impurity)
OR1006312(S, E) -4- (Dimethylamino) -N- (4-hydroxy-7- ((tetrahydrofuran-3-yl) oxy) quinazolin-6-yl) but-2-enamide (Afatinib Impurity)
PC110166(S, E) -4- (Dimethylamino) -N- (4- ((4-fluorophenyl) amino) -7- ((tetrahydrofuran-3-yl) oxy) quinazolin-6-yl) but-2-enamide (Afatinib Impurity)
PC109941(S, E) -N- (4- ((3-Chloro-4-fluorophenyl) amino) -7- ((tetrahydrofuran-3-yl) oxy) quinazolin-6-yl) but-2-enamide (Afatinib Impurity)

Popular Products